Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies

被引:2
|
作者
DeRosier, Frederick [1 ]
Hibbs, Cody [1 ]
Alessi, Kaitlyn [2 ]
Padda, Inderbir [3 ]
Rodriguez, Jeanette [4 ]
Pradeep, Swati [5 ]
Parmar, Mayur S. [1 ]
机构
[1] Nova Southeastern Univ, Dr Kiran C Patel Coll Osteopath Med, Dept Fdn Sci, Clearwater, FL 33759 USA
[2] Univ Florida, Dept Family Med, Gainesville, FL USA
[3] Richmond Univ, Med Ctr, Dept Internal Med, Staten Isl, NY USA
[4] Nova Southeastern Univ, Dr Kiran C Patel Coll Osteopath Med, Dept Family Med, Clearwater, FL USA
[5] UTHlth Houston Neurosci Neurol Texas Med Ctr, Dept Movement Disorders, Houston, TX USA
来源
DM DISEASE-A-MONTH | 2024年 / 70卷 / 08期
关键词
Progressive supranuclear palsy; Pathophysiology; Clinical diagnosis; Imaging; Treatment and managment; Emerging therapies; PARKINSONS-DISEASE; TAU; PATHOLOGY; DISORDERS; COGNITION; SURVIVAL; ATROPHY; HEALTH; SPECT; RISK;
D O I
10.1016/j.disamonth.2024.101753
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by the accumulation of 4R-tau protein aggregates in various brain regions. PSP leads to neuronal loss, gliosis, and tau-positive inclusions, such as neurofibrillary tangles, tufted astrocytes, and coiled bodies. These pathological changes mainly affect the brainstem and the basal ganglia, resulting in distinctive MRI features, such as the hummingbird and morning glory signs. PSP shows clinical heterogeneity and presents as different phenotypes, the most classical of which is Richardson's syndrome (PSP-RS). The region of involvement and the mode of atrophy spread can further distinguish subtypes of PSP. PSP patients can experience various signs and symptoms, such as postural instability, supranuclear ophthalmoplegia, low amplitude fast finger tapping, and irregular sleep patterns. The most common symptoms of PSP are postural instability, falls, vertical gaze palsy, bradykinesia, and cognitive impairment. These features often overlap with those of Parkinson's disease (PD) and other Parkinsonian syndromes, making the diagnosis challenging. PSP is an essential clinical topic to research because it is a devastating and incurable disease. However, there are still many gaps in knowledge about its pathophysiology, diagnosis, and treatment. Several clinical trials are underway to test noveltherapies that target tau in various ways, such as modulating its post-translational modifications, stabilizing its interaction with microtubules, or enhancing its clearance by immunotherapy. These approaches may offer new hope for slowing down the progression of PSP. In this review, we aim to provide an overview of the current knowledge on PSP, from its pathogenesis to its management. We also discuss the latest advances and future directions in PSP research. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy
    Owens, Emily
    Krecke, Karl
    Ahlskog, J. E.
    Fealey, Robert
    Hassan, Anhar
    Josephs, Keith A.
    Klassen, Bryan
    Matsumoto, Joseph
    Bower, James
    PARKINSONISM & RELATED DISORDERS, 2016, 28 : 107 - 111
  • [42] Progressive supranuclear palsy: Advances in diagnosis and management
    Coughlin, David G.
    Litvan, Irene
    PARKINSONISM & RELATED DISORDERS, 2020, 73 : 105 - 116
  • [43] Anesthetic management of a patient with progressive supranuclear palsy
    Sakai K.
    Sumikawa K.
    Journal of Anesthesia, 2006, 20 (4) : 312 - 313
  • [44] Natural history and clinical features of progressive supranuclear palsy: a clinical study
    C. Diroma
    C. Dell’Aquila
    A. Fraddosio
    S. Lamberti
    R. Mastronardi
    I. Russo
    M. De Mari
    G. Iliceto
    Neurological Sciences, 2003, 24 : 176 - 177
  • [45] Clinical genetics of familial progressive supranuclear palsy
    Rojo, A
    Pernaute, RS
    Fontán, A
    Ruíz, PG
    Honnorat, J
    Lynch, T
    Chin, S
    Gonzalo, I
    Rábano, A
    Martínez, A
    Daniel, S
    Pramsteller, P
    Morris, H
    Wood, N
    Lees, A
    Tabernero, C
    Nyggard, T
    Jackson, AC
    Hanson, A
    de Yébenes, JG
    BRAIN, 1999, 122 : 1233 - 1245
  • [46] A clinical rating scale for progressive supranuclear palsy
    Golbe, Lawrence I.
    Ohman-Strickland, Pamela A.
    BRAIN, 2007, 130 : 1552 - 1565
  • [47] Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
    Street, Duncan
    Malpetti, Maura
    Rittman, Timothy
    Ghosh, Boyd C. P.
    Murley, Alexander G.
    Coyle-Gilchrist, Ian
    Passamonti, Luca
    Rowe, James B.
    BRAIN COMMUNICATIONS, 2021, 3 (03)
  • [48] Progressive supranuclear palsy: clinical and genetic aspects
    Pastor, P
    Tolosa, E
    CURRENT OPINION IN NEUROLOGY, 2002, 15 (04) : 429 - 437
  • [49] Clinical pain and experimental pain sensitivity in progressive supranuclear palsy
    Stamelou, Maria
    Dohmann, Helena
    Brebermann, Juliane
    Boura, Evangelia
    Oertel, Wolfgang H.
    Hoeglinger, Gunter
    Moeller, Jens C.
    Mylius, Veit
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (05) : 606 - 608
  • [50] Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy
    Tsai, Richard M.
    Lobach, Iryna
    Bang, Jee
    Whitwell, Jennifer L.
    Senjem, Matthew L.
    Jack, Clifford R., Jr.
    Rosen, Howard
    Miller, Bruce
    Boxer, Adam L.
    PARKINSONISM & RELATED DISORDERS, 2016, 28 : 29 - 35